| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2326428-19-5 | [Synonyms]
CDK7-IN-2
LY-3405105
(S,E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate
1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)-1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester | [Molecular Formula]
C26H39N7O3 | [MOL File]
2326428-19-5.mol | [Molecular Weight]
497.63 |
| Chemical Properties | Back Directory | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (200.95 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.26±0.28(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1]. | [References]
[1] David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1. |
|
|